Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study

Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study

This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of Bictegrav...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2024-09
Hauptverfasser: Joly, Véronique, Ferre, Valentine M, Le Hingrat, Quentin, Peytavin, Gilles, Cresta, Mélanie, Charpentier, Charlotte, Digumber, Marc, Damond, Florence, Yazdanpanah, Yazdan, Matheron, Sophie, Descamps, Diane, Ghosn, Jade
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of Bictegravir/FTC/TAF to treat HIV-2 infection.
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciae447